When it comes to manufacturing CAR T drugs
(personalized treatments engineering immune cells to destroy cancer cells of patients) speed is of utmost importance. A new manufacturing site has been decided upon by Gilead for Yescarta, its CAR-T therapy at a Netherlands airport.
In a statement released by Gilead company Kite, it was stated that a 117,000 square-foot has been leased in Hoofddorp at the SEGRO Park Amsterdam Airport. Though the investment details for the facility were not clear, it has been estimated that when it becomes fully operational in 2020, it is expected to have 300 employees.
The FDA granted approval to Yescarta in last fall for treatment of adults suffering from relapsed or refractory large B-cell lymphoma, which includes non-Hodgkin lymphoma, in the event of failure of two or more traditional treatment regimens. The treatment is presently under review by regulators in Europe and is priced at USD 375,000 in the U.S.
The new European manufacturing facility will facilitate the manufacturing of personalized cell therapies with an emphasis on closer geographic proximity for patients receiving them. The closer location is intended to reduce turnaround time for patients in need of urgent care.
Yescarta was approved by the FDA last fall to treat adults with relapsed or refractory large B-cell lymphoma, including aggressive non-Hodgkin lymphoma, who have failed two or more traditional treatments. It is priced at $375,000 in the U.S. and is currently under review by regulators in Europe.
“This new European manufacturing facility will enable personalized cell therapies to be manufactured in closer geographic proximity to the patients who will receive them, potentially shortening the turnaround time for people who urgently need care.
Kite also stated that a new building has been acquired by it in Santa Monica, California for clinical manufacturing and cell therapy R&D. By Ddu
Copyright©2018 Ddu. All rights reserved.